Skip to main content
. 2022 Apr 5;15(4):450. doi: 10.3390/ph15040450

Figure 10.

Figure 10

Studies involving gefitinib (blue), erlotinib (green: preclinical, orange: clinical), afatinib (red), and osimertinib (gray).